IL2 and neoplasm: Four weeks after tumor injection, mice that had received HMB-PP plus IL-2-treated (activated and expanded over 12 days) γδ PBL showed significantly reduced tumor load (derived from Molt-4 leukemia cells) compared to control mice that did not receive γδ T-cells (Figures 6C–E).